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Minimal residual disease  
When acute lymphoblastic leukemia is diagnosed in a
patient, the total number of leukemia cells is 
approximated to 1012 to 1013. A majority of patients 
reach complete remission (CR) after about 4 weeks of 
chemotherapy. Complete remission does not mean that 
leukemia cells are totally eradicated from the body but 
that their level is beyond the sensitivity level of
classical cytomorphologic methods (e.g. 1 to 5%). At 
this time, up to 1010 malignant cells can still remain in 
the patient. They represent the minimal residual disease 
(MRD). Techniques which are more sensitive than 
cytomorphology are now available that permit to detect 
these residual blasts (reviewed in (Campana and Pui, 
1995; Foroni et al., 1999)). 
Detection of residual cells allows a longer follow-up of 
the tumor burden during chemotherapy and thus, 
permits to better appreciate the sensitivity of leukemia 
cells to treatment. It is now established that the lev l of 
MRD represents a powerful prognostic factor. Besides, 
the detection of an increase of the MRD level enables 
to anticipate impending relapse.  
Techniques for the follow-up of the 
residual disease  
Techniques aimed at studying MRD rely on the 
detection of a leukemia cell specific marker which 
enable to distinguish blasts from normal marrow cells. 
Such markers have to be detected with high sensitivity, 
to be present in all leukemia cells and to be stable 
during disease evolution. Two kinds of markers are 
currently used: genetic markers, which can be detect d 
by PCR, and immunophenotypic markers, which can be 
detected by flow cytometry.  
PCR-bases techniques  
PCR based strategies can be directed to 2 types of 
genetic targets: breakpoints of leukemia-related 
chromosome aberrations, and antigen-receptor gene 
rearrangements. The extreme sensitivity of polymerase 
chain reaction (PCR) makes possible the consistent 
detection of 1 leukemia cell among 105 normal cells 
(10-5). 
Chromosome aberration 
Recurrent chromosome translocations are found in 30 
to 40% of ALL (figure 1) (Pui. and Evans, 1998). The 
molecular counterpart of these translocations can be 
detected by PCR using primers located on each side of 
the breakpoint (Pui. and Evans, 1998). DNA 
amplification can only be used for chromosome 
aberrations in which breakpoints cluster in a small area, 
such as Tal-1 deletions or Ig-cMyc fusions. In most 
cases, breakpoints spread over large intronic regions, 
but translocations give rise to fusion transcripts suitable 
for PCR amplification after a reverse transcription step 
(RT-PCR). All fusion transcripts can be used as 
markers for MRD follow-up. Their detection in 
remission samples is achieved, as for diagnosis, by RT-
PCR. The detection sensitivity depends upon both the 
amount of RNA studied and the level of expression of 
the transcript. When 1-2 ug of RNA is studied, fusion 
transcripts associated to ALL permit to detect residual 
blasts with a sensitivity of 10-4 to 10-6.  
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Figure 1: Frequencies of the main fusion genes which can be used as PCR targets for MRD monitoring in ALL 
 
The main advantage of such markers is to be directly 
involved in leukemogenesis. Accordingly, their 
presence is constant all over disease evolution. 
However, variations in their expression level during the 
disease and particularly during chemotherapy cannot be 
excluded. This makes difficult to correlate the level of 
detection of a transcript to the amount of leukemia 
cells. 
Given the frequency of each translocation, each fusion 
transcript permits to study only a subset of patients 
(figure 1). Another inconvenient is that, because th y 
are not patient specific, these PCR targets are much 
more prone to false positive results due to carry-over 
than antigen-receptor genes. 
Antigen-receptor gene rearrangements 
The use of antigen-receptor gene rearrangements for 
MRD detection has been developed in order to 
overcome the lack of recurrent chromosomal 
abnormalities in most of the patients with lymphoid 
malignancies. In ALL, T-cell receptor (TcR) and 
immunoglobulin (Ig) loci undergo somatic 
rearrangement by V(D)J recombination without strict 
lineage specificity. Provided the extreme diversity 
created by V(D)J rearrangements, each malignant cloe 
will present a specific configuration and the sequence 
of the junctional region(s) (N-region) is highly clone-
specific. For technical convenience, rearrangements 
studied for MRD follow up are those of TcRgamma-
delta, Ig heavy chain (IgH) and Igkappa. The frequency 
of these rearrangements in ALL is indicated in table 2. 
A combined study of these 4 loci permits to identify 
one or more rearrangement in virtually all cases of 
ALL. 
All rearrangement-based PCR techniques use the same
general strategy (fig.2) (Hanssen-Hagge et al., 1989; 
Macintyre et al., 1990). The presence of 
rearrangements in leukemia blasts is searched in a 
marrow sample obtained at diagnosis. PCR reactions 
are conducted using different combinations of V andD 
or J specific primers. When a rearrangement is present 
in leukemia cells, an intense and one-sized PCR signal 
is obtained. PCR products are then sequenced to derive 
either an oligonucleotidic probe or a primer specific for 
the junctional sequence of each specific clone. Test for 
MRD is conducted by PCR amplification of DNA from 
remission marrow cells, with the use of primer sets 
corresponding to the clonal rearrangement identified at 
the time of diagnosis. PCR products are then 
hybridized to the radiolabeled clono-specific probe. 
Alternatively, a primer specific of the junctional region 
can be used for nested PCR. A positive signal 
corresponds to the presence of residual blasts in the 
remission sample. This strategy permits to reach a 
sensitivity of 10-4 to 10-5 when 1-2 ug of DNA from 
the remission sample is studied. Performing PCR 
replicates permits to study a higher amount of DNA 
and thus, to reach a higher sensitivity (Roberts et al., 
1997).  
 
Table 1: Frequency of TcR and Ig recombination in childhood 
ALL (For some rearrangements, frequencies are slightly 
different in adult ALL). 
  
- B-lineage ALL T-lineage ALL 
IgH >90%  10-15% 
Igkappa* 50% 0%  
TcRdelta** 55% 50% 
TcRgamma 55% 90%  
*Igkappa deletional rearrangements (Kde) 
**The more frequent TcRdelta rearrangements are Vdelta2-
Ddelta3 and Ddelta2-Ddelta3 in B-lineage ALL and Vdelta2-
Ddelta3, Vdelta1-J1delta and Ddelta2-Jdelta1 in T-ALL. 
 
The major advantage of antigen-receptor gene 
rearrangements is that they permit to study MRD in 
almost of cases of ALL. However, the need to sequence 
one or more rearrangement(s) in each patient makes the 
technique time-consuming and costly. Rather than by 
their sequence, rearrangements can be characterised by 
their size, and detected by resolutive electrophoresis on 
an automated sequence analyser. This simplification 
makes easier routine detection of MRD but leads to an 
important loss of sensitivity. It is thus mostly suited to 
the follow-up during the early steps of treatment. 
A second advantage is that DNA is less fragile than 
RNA and makes easier the standardisation of the 
amount of material studied. This is important to 
determine the sensitivity of the detection in case of a 
negative result. 
However, the use of clonal markers has a main 
limitation: the stability of the markers during the 
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be absent on blasts responsible for relapse. Marker 
instability is usually due to the fact that the marker 
identified at diagnosis was only present on a sub-clone 
of blasts, which is not responsible for the relapse. This 
phenomenon is termed "oligoclonality" (Deane and 
Norton, 1991). Another possibility is that the clonal 
marker is replaced by a secondary rearrangement. This 
is termed " clonal evolution " (Bird et al., 1988). 
Comparison of clono-specific markers present at 
diagnosis and at relapse reveals changes in 
rearrangement patterns in up to 40% of IgH 
rearrangements and 7-20% of TcRgamma-delta 
rearrangements. However, at least one allele remains 
stable in about 90% of cases (Marshall et al., 1995). In 
this respect, the use of several markers is recommended 
to prevent false negative results. Although MRD 
detection can be hampered by markers instability, it is
noteworthy that the probability of changes in 
rearrangement pattern increases with time (Marshall et 
al., 1995). Thus, the risk of a false negative result i  




Figure 2: General strategy for MRD assessment using antigen 
receptor gene rearrangements as clonal markers. 
 
Quantitative aspect 
It is well establish now that quantitative MRD data 
have a higher predictive value than qualitative ones 
(Brisco et al., 1994; Cave et al., 1998; van Dongen et 
al., 1998). Moreover, sensitivity of the assay, which 
varies with the marker used and the specimen studied, 
has to be accurately determined in order to be ableto 
interpret negative results. Quantitative techniques are 
thus required. Strategies such as limiting dilutions 
(Roberts et al., 1997; Brisco et al., 1994) or competitive 
PCR (Cave et al., 1994; van Rhee et al., 1995) have 
been used to make PCR-based assays quantitative. 
However, these techniques have been restricted to 
specialised laboratories. It is now possible to detect 
PCR product formation in " real-time " during 
amplification reaction and to determine PCR kinetics, 
which is related to the amount of targets in the tube. 
The recent development of semi-automated quantitative 
assays based on this technology (or "real-time PCR") 
(Heid et al., 1996) encouraged many laboratories to 
develop quantitative MRD assays using either fusion 
transcripts, or antigen-receptor gene rearrangements. 
Immunological techniques  
Although leukemia cells are believed to be the 
malignant counterpart of normal cells at different 
stages of differentiation, they often display aberrant or 
unusual antigen expression. Multiparameter-flow 
cytometry permits to detect various combinations of 
surface membrane, cytoplasmic and nuclear molecules 
expressed or overexpressed by leukemia cells but not 
by normal bone marrow cells. Depending on the 
strategy used, 60 to 80% of childhood ALL present a 
leukemia-specific immunophenotype (Coustan-Smith 
et al., 1998; Farahat et al., 1998). Multiparameter-flow 
cytometry enables to detect residual blasts with a 
sensitivity level of 10-4 (Coustan-Smith et al., 1998; 
Farahat et al., 1998), which is slightly below the 
sensitivity of molecular methods. Unlike molecular 
methods, flow cytometry discriminates between viable 
and dead cells. The main advantages of flow cytometry 
is that it directly give quantitative data and is very rapid 
(results can be obtained in 24h). The stability of 
immunological markers over the course of the disease 
is yet to be determined. 
Clinical significance of minimal 
residual disease in ALL  
Sequential follow-up of MRD in childhood ALL 
The clinical significance of MRD assessment has 
remained controversial for a long time mostly because 
the first clinical studies were conducted retrospectiv ly 
on small and heterogeneous groups of patients 
undergoing different treatments. More recently, large 
prospective studies of serial bone marrow specimen 
unequivocally demonstrated that MRD assessment give 
clinically relevant insight into the effectiveness of
treatment. 
Most studies investigating the value of measuring 
MRD in bone marrow used antigen-receptor gene 
rearrangements as PCR targets. The first large study 
was retrospective and included 88 children enrolled in 
2 therapeutic trials (Australian and New Zealand 
Children's Cancer Study IV and V) (Brisco et al., 
1994). The level of residual blasts was quantified using 
limiting dilution analysis. More recently, results of two 
multicenter European prospective studies have been 
reported. One studied MRD on a semi-quantitative 
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basis in 240 children treated according to the natio l 
protocols of the BFM (Berlin-Frankfurt-Munchen) 
protocol (Cave et al., 1998). The other studied MRD in 
178 children treated according to the EORTC 
(European Organisation for research and treatment of 
Cancer) protocol 58 881 (van Dongen et al., 1998). In 
this latter study, residual blasts were quantified using a 
competitive PCR assay. The largest study using 
immunological markers report the follow-up of 65 
patients (Coustan-Smith et al., 1998).  
Although differences were noted according to treatment 
intensity, conclusions of these studies were virtually the 
same:  
• Residual blasts are still detected after completion of 
induction therapy in approximately 50% of children 
treated for ALL. This percentage can vary according to 
the intensity of the chemotherapy regimen and MRD 
results have to be interpreted in relationship with the 
type of treatment (Brisco et al., 1994).  
• MRD is closely related to the risk of relapse during 
all the course of chemotherapy and can be used as a 
prognostic factor as soon as induction therapy is 
completed. This suggests that the sensitivity to drugs 
administered during induction therapy correlates 
closely with the sensitivity to agents during later 
therapy. 
• The risk of relapse rises steeply with the amount of 
residual blasts, and the extent of MRD predict the 
outcome more precisely than simple presence or 
absence. More than 70% of children with MRD levels 
above 10-2 at the end of induction therapy relapsed, as 
compared to less than 10% of the children with MRD 
levels below 10-4 (Cave et al., 1998; van Dongen et al., 
1998). 
• MRD is independent from other prognostic factors 
such as immunophenotype, white blood count, age, and 
corticosteroid response. Thus, MRD provides a 
predictive factor in virtually all subgroups of patients 
with ALL. 
• The occurrence of individual relapse is not always 
predicted, especially for extra-medullary and off-
therapy relapses. This is not due to a lack of sensitivity 
of MRD detection since a large proportion of children 
who are not going to relapse have weakly positive 
signals. Other factors must be involved.  
Sequential follow-up of MRD in adult ALL 
MRD has been less extensively studied in adult thanin 
childhood ALL and studies have only been conducted 
on few patients. As for children, the level of MRD at 
the end of induction therapy predicts clinical outcme. 
Comparison of MRD results found in children who 
received similar induction therapy indicates that adult 
ALL are more resistant to treatment even in the 
absence of a t(9 ;22) (Brisco et al., 1996; Foroni et al., 
1997). This is consistent with the fact that adult patients 
have a worse overall outcome than children do. It is not 
clear whether the increased resistance to chemotherapy 
observed in adults is age- or leukemia related. 
MRD measurement in blood samples 
The level of residual blasts in peripheral blood is 
proportional to that in bone marrow but is about ten
times lower (Marshall et al., 1995; van Rhee et al., 
1995; Brisco et al., 1997). For this reason, bone 
marrow is considered as the best tissue source to study
MRD. 
MRD evaluation in bone marrow transplantation 
Very few data concerns the prognostic information 
provided by MRD assessment for patients who 
underwent bone marrow transplantation (BMT). 
Recently, one group retrospectively studied MRD 
status before (Knechtli et al., 1998) and after (Knechtli 
et al., Br J Haematol, 1998) allo-BMT in a series of 64 
patients. Their result suggests that pre-and post-
transplant MRD levels correlate significantly with t e 
risk of medullar relapse. Unfortunately, data were 
presented separately, which makes impossible to 
evaluate the individual relationship between pre- and 
post-BMT status of the patients. Moreover, 
transplantation with T-depleted unrelated donors were 
largely over-represented and results might not have a 
general significance. However, MRD assessment 
should be useful to monitor of emerging therapies such 
as donor lymphocyte infusion or immunotherapy. As in 
the case of first-line therapy, quantitative data might 
help to predict with more accuracy patient outcome 
after allo-BMT (Knechtli et al., Br J Haematol, 1998). 
Conclusion 
Although certain presenting features are statistically 
correlated with the prognosis of ALL, the outcome 
remains largely unpredictable for most of the patients 
whatever the initial seriousness of the disease. The
level of MRD provides a measure of kinetics of tumor 
reduction, giving insights into the in-vivo resistance of 
the overall leukemic population to the 
chemotherapeutic agents used. In-vivo, drug resistance 
appears partly independent from the prognostic factors 
at presentation an probably involves additional 
constitutional factors determining drug metabolism for 
instance. Early response predicts long-term outcome. In 
this respect, MRD assessment complements other 
methods for early evaluation of the response to 
chemotherapy such as corticoresistance or D15 bone 
marrow aspirate examination. It has been shown that 
MRD at the end of induction therapy provides a 
prognostic factor independently of corticoresistance. 
Probably because at this time, more drugs have been
administered. The benefit of MRD assessment over 
D15 bone marrow aspiration has not been evaluated. 
D15 bone marrow aspiration is less costly but difficult 
to estimate reliably and reproducibly. 
New therapeutic trials already integrate MRD results to 
therapeutic decisions. The problem is now to determine 
what is the best to do for patients who are resistant to 
treatment.  
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